Wenjuan Liu

Wenjuan Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YSYa-Wen Sun
Ya-Wen Sun
JXJian Xu
Jian Xu
JZJun Zhou
Jun Zhou
WLWenjuan Liu
Wenjuan Liu
Targeted drugs for systemic therapy of lung cancer with brain metastases Targeted drugs for systemic therapy of lung cancer with brain metastases

16 July 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
WLWenjuan Liu
Wenjuan Liu
XLXiu-Jun Liu
Xiu-Jun Liu
JXJian Xu
Jian Xu
LLLiang Li
Liang Li
YLYi Li
Yi Li
YZYongsu Zhen
Yongsu Zhen
Defensins play an essential role in innate immunity. In this study, a novel recombinant β-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting β-defensin consists of an EGF-derived oligopeptide (Ec), a β-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the “scaffold” for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cytotoxicity of Ec-LDP-hBD1 to EGFR highly expressed A431 cells was more potent than that to EGFR low-expressed human lung carcinoma A549 and H460 cells (the IC50 values in A431, A549, and H460 cells were 1.8 ± 0.55, 11.9 ± 0.51, and 5.19 ± 1.21 μmol/L, respectively); in addition, the cytotoxicity of Ec-LDP-hBD1 was much stronger than that of Ec-LDP and hBD1. Moreover, Ec-LDP-hBD1 suppressed cancer cell proliferation and induced mitochondria-mediated apoptosis. Its in vivo anticancer action was evaluated in athymic mice with A431 and H460 xenografts. The mice were administered Ec-LDP-hBD1 (5, 10 mg/kg, i.v.) two times with a weekly interval. Administration of Ec-LDP-hBD1 markedly inhibited the tumor growth without significant body weight changes. The in vivo imaging further revealed that Ec-LDP-hBD1 had a tumor-specific distribution with a clear image of localization. The results demonstrate that the novel recombinant EGFR-targeting β-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against relevant cancer cells by inducing mitochondria-mediated apoptosis and exhibits high therapeutic efficacy against the EGFR-expressed carcinoma xenograft. This novel format of β-defensin, which induces mitochondrial-mediated apoptosis, may play an active role in EGFR-targeting cancer therapy.

1 June 2017 in Precision Radiation Oncology
Verified
Journal Article
Open access
PDF file
WLWenjuan Liu
Wenjuan Liu
XSXianrang Song
Xianrang Song
BZBin-Li Zuo
Bin-Li Zuo
XWXing-Wu Wang
Xing-Wu Wang
It is well known that α-defensins are mainly packaged in neutrophil granules (HNP1, HNP2, and HNP3) or secreted by intestinal Paneth cells (human defensin [HD]5 and HD6). HNP1–3 peptides are also secreted, and their accumulation in biological fluids was proposed as a tumor biomarker. It has been reported that α-defensins promote tumor cell growth, but also provoke cell death at higher concentrations. The aim of the present study was to construct a novel fusion protein consisting of oligopeptides specific for human epidermal growth factor receptor (EGFR), lidamycin apoprotein (LDP), and HD5, and investigate its anti-pancreatic cancer activities. HD5 was fused to the Ec-LDP protein to obtain the Ec-LDP-D5 fusion protein by DNA recombination. Then, immunofluorescence and enzyme-linked immunosorbent assays were used to investigate the binding activities of Ec-LDP-D5 to EGFR-overexpressed cancer cells. CCK-8 assay was used to measure Ec-LDP-D5 in vitro cytotoxicity, and AnnexinV-FITC/PI staining assay was used to analyze its apoptosis-inducing efficacy. The Ec-LDP-D5 fusion protein was constructed correctly and expressed in Escherichia coli in insoluble inclusion bodies. The production of Ec-LDP-D5 was 1 mg/L fermentation broth, and the purity of the fusion protein was 85% as analyzed by high-performance liquid chromatography. Ec-LDP-D5 showed strong binding activities for pancreatic cancer cells that highly express EGFR, including PNAC-1 and Aspc-1 cells. The Ec-LDP-D5 fusion protein showed more potent cytotoxicity to cancer cells compared with Ec-LDP. The results from the AnnexinV-FITC/PI staining assay also revealed that Ec-LDP-D5 significantly induced cell apoptosis. The novel Ec-LDP-D5 fusion protein binds to EGFR specifically, and shows potent cytotoxicity and apoptosis-inducing activities towards pancreatic cancer cells, which suggests that it would be a promising cancer therapeutics candidate.